CORT
CORCEPT THERAPEUTICS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 15 Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics…
- Jul 23 Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics…
- Jul 27 ▼ Wolfe Research downgrades
- Sep 2 ▼ 1 insider sell $5.6M at $110.24
- Sep 2 Trial readout: T-90d Trial Readout: relacorilant (Phase 2)
- Sep 14 to Sep 16 ▼ 3 days of insider sells: $2.3M by 3 insiders, avg $111.93
- Sep 14 Trial readout: T-90d Trial Readout: relacorilant (Phase 2)
- Oct 1 to Oct 2 ▼ 2 days of insider sells: $5.0M by 3 insiders, avg $116.19
- Oct 15 ▼ 1 insider sell $1.1M at $114.81
- Nov 2 to Nov 10 ▼ 3 days of insider sells: $2.8M by 3 insiders, avg $81.29
- Nov 3 ▲ Corcept Therapeutics reported Q3 2026 revenue of $340.5M (+64% YoY)…
- Nov 3 ▲ Earnings: CORT Q3 2026 Earnings: EPS $1.01 (+24.7% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $16.9M.
- InstitutionsBULLISH
Q2 2026: 44 added (2 new), 24 trimmed or exited. Largest new: Fuller & Thaler Asset Management, $61.7M, Jacobs Levy Equity Management $60.5M.
- AnalystsBULLISH
10 of 12 rate it Buy or better. Median target $164.00 (+138%).
- Short sellersSTEADY
Short interest +6.3% to 9.13M shares. 8.1 days to cover, ≈8.3% of shares.
- TrendDOWNTREND
33% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| D. E. Shaw & Co., Inc. | TRIM | $76.8M |
| FULLER & THALER ASSET MANAGEMENT, INC. | NEW | $61.7M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | NEW | $60.5M |
| Allspring Global Investments Holdings, LLC | DOUBLED | $46.3M |
| NORGES BANK | TRIM | $42.3M |
| Nuveen, LLC | DOUBLED | $33.7M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $28.6M |
| JPMORGAN CHASE & CO | ADD | $22.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is inside the target range. Median implies +138%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Piper Sandler REITERATE | Overweight |
| Sep 18, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jul 30, 2026 | Piper Sandler REITERATE | Overweight |
| Jul 30, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Jul 30, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Swisher Daniel N JR Director Nov 10, 2026 | EXERCISE | $4.2K |
Swisher Daniel N JR Director Nov 10, 2026 | SELL | $111.1K |
Swisher Daniel N JR Director Nov 10, 2026 | EXERCISE | $15.5K |
Maduck Sean Nov 3, 2026 | EXERCISE | $108.8K |
Maduck Sean Nov 3, 2026 | SELL | $706.8K |
Maduck Sean Nov 3, 2026 | SELL | $375.5K |
Maduck Sean Nov 2, 2026 | SELL | $964.1K |
Maduck Sean Nov 2, 2026 | EXERCISE | $97.9K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.84 | $0.60–$1.09 | -12.9% | $374.2M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
36 filings · 6 bullish · 5 bearish · 25 neutral- NEUTRAL CLUSTERNov 13, 2026
Two insiders at Corcept Therapeutics sold shares in the week following a strong Q3 earnings…
Sales are small and pre-planned, so no bearish signal. The key catalyst remains the December 17 PDUFA date for relacorilant. Monitor for any insider buying ahead of that event, which would be more…
- NEUTRAL 144Nov 10, 2026
Director Daniel Swisher Jr. filed a Form 144 notice of intent to sell 1,500 shares of Corcept…
The sale is small and routine for a director; no material impact expected. Monitor for any larger insider sales or changes in insider filing patterns ahead of the next earnings report.
- NEUTRAL CLUSTERNov 4, 2026
Two insiders at Corcept Therapeutics sold a combined $1.50M in open-market shares on November 2-3…
The insider sales are small, plan-based, and follow a strong earnings report. No negative signal; monitor the December 17 PDUFA date for relacorilant as the next catalyst.
- BULLISH 8-KNov 3, 2026
Corcept Therapeutics reported Q3 2026 revenue of $340.5M (+64% YoY) and diluted EPS of $1.01, well…
The strong Q3 beat and reiterated guidance signal accelerating commercial execution from both Korlym and Lifyorli. The key near-term catalyst is the December 17 PDUFA date for relacorilant in…
All CORT filing & press-release reports (36)
- CLUSTER reportNov 13, 2026
- 144 reportNov 10, 2026
- CLUSTER reportNov 4, 2026
- 8-K reportNov 3, 2026
- INST-CLUSTER reportNov 2, 2026
- SC 13G/A reportOct 27, 2026
- CLUSTER reportOct 5, 2026
- 8-K reportSep 23, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 6, 2026
- CLUSTER reportAug 5, 2026
- COURT-RULING reportJul 23, 2026
- CLUSTER reportJul 17, 2026
- COURT-RULING reportJul 15, 2026
- CLUSTER reportJul 8, 2026
- 8-K reportJun 17, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportJun 2, 2026
- 8-K reportJun 3, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 1, 2026
- CLUSTER reportMar 20, 2026
- CLUSTER reportMar 17, 2026
- 8-K reportFeb 24, 2026